Status:
UNKNOWN
Identification of Predictive and Prognostic Markers for Lung Cancer With Metastases
Lead Sponsor:
Janna Berg
Collaborating Sponsors:
Oslo University Hospital
Conditions:
Lung Cancer
Primary Tumor
Eligibility:
All Genders
18-90 years
Phase:
NA
Brief Summary
The project aims to compare the histopathological and molecular characteristics of tumour tissue from metastases with similar analyses of the primary tumour in the lung, where it is available. The in...
Detailed Description
The investigators want to make genome analysis of tissue samples. This involves analysing the RNA, DNA methylation, for example in cancer cells. This will provide information regarding somatic changes...
Eligibility Criteria
Inclusion
- Patients with metastasizing lung cancer where further treatment is still applicable.
Exclusion
- Terminal patients or patients in a reduced general condition with EGOC 3-4, i.e. patients who are confined to bed more than 50% of the day, with no clinical indication to perform sampling of the tumor and metastases.
- Patients where further cancer treatment is no longer applicable.
- Patients with cognitive impairment.
- Patients with inaccessible metastases where sampling may cause distress to the patient and are at increased risk of complications.
Key Trial Info
Start Date :
December 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2025
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT02301858
Start Date
December 1 2013
End Date
December 1 2025
Last Update
January 23 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Vestfold Hospital Trust
Tønsberg, Norway, 3103